Sonnet Biotherapeutics

SONN

US83548R4020

Market Closed - Nasdaq 05:00:00 03/12/2025 HKT			5-day change	1st Jan Change
1.260 ^USD	-59.35%		-.--%	-

12-17	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-03	Top Midday Decliners	MT

Top Midday Decliners

Published on 12/03/2025 at 03:26 am HKT

MT Newswires

This article is reserved for our members.

Continue with Google Continue with Apple Continue with LinkedIn

or by email

Continue with an email.

Latest news about Sonnet Biotherapeutics

12-17	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-03	Top Midday Decliners	MT
12-02	Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies	RE
12-02	Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index	CI
12-02	Hyperliquid Strategies Inc completed the acquisition of Sonnet BioTherapeutics Holdings, Inc. in a reverse merger transaction.	CI
15/10/25	Sonnet BioTherapeutics Holdings, Inc. Collaborates with Spanishos on Non-Clinical Study Using New Alternate Methodologies Based Patient-Derived Tumoroid Platform	CI
15/09/25	Top Premarket Decliners	MT
14/08/25	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
11/08/25	Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer	CI
04/08/25	Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study	MT
04/08/25	Sonnet Biotherapeutics expands trial of SON-1010 with atezolizumab in advanced ovarian cancer	RE
04/08/25	Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	CI
15/07/25	Top Premarket Decliners	MT
15/07/25	Top Midday Gainers	MT
14/07/25	Traders Digest Tariff Announcements, Driving Premarket Losses for US Equity Futures	MT

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Employees

Sector

More about the company